{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-009982","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.290959+00:00","generated_at":"2026-05-24T01:54:03.279762+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Monopar Therapeutics reports Q4 2024 net loss $10.9M; cash $60.2M; ALXN1840 NDA planned early 2026","bullets":["Q4 2024 net loss $10.9M ($2.23/share) vs $1.8M ($0.60/share) in Q4 2023.","FY2024 net loss $15.6M ($4.11/share) vs $8.4M ($3.04/share) in FY2023; R&D expenses rose to $13.0M from $5.6M.","Cash and short-term investments $60.2M at Dec 31, 2024; expects runway through Dec 31, 2026.","Plan to submit NDA for ALXN1840 (Wilson disease) to FDA in early 2026.","Raised net proceeds ~$55M from Q4 2024 financings; MNPR-101-Lu Phase 1a dosed first patient in December 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-009982","json":"https://secwatch.observer/filing/0001437749-25-009982.json","markdown":"https://secwatch.observer/filing/0001437749-25-009982.md","text":"https://secwatch.observer/filing/0001437749-25-009982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925009982/0001437749-25-009982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925009982/mnpr20250326_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:54:03.279762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}